Skip to main content
See every side of every news story
Published • loading... • Updated

Innogen Pharmaceuticals Enters Into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion

The agreement gives Arcera rights to pursue approvals and commercialization of Efsubaglutide Alfa in selected markets, with payments worth more than $1 billion.

Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries in Africa, Latin America, the Middle East and Eastern Europe, while Innogen retains the relevant rights in the rest of the world.Under the agreement, Innogen will…

6 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 40% of the sources lean Left, 40% of the sources lean Right
40% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Thursday, November 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal